FIRST AMENDMENT TO THE NON-DISCLOSURE AGREEMENT
Exhibit (d)(4)
FIRST AMENDMENT
TO THE NON-DISCLOSURE AGREEMENT
This First Amendment (“Amendment”) to the Non-Disclosure Agreement, dated November 5, 2020 (“Agreement”) is effective as of the date of the last signature below (the “Amendment Effective Date”), and is made and entered into between:
MorphoSys AG, a publicly listed German corporation (registered at the Local Court of Munich HRB 121023) having an office and place of business at Xxxxxxxxxxxxxxxxx 0, 00000 Xxxxxxx, Xxxxxxx (“MORPHOSYS”)
and
Constellation Pharmaceuticals, Inc., a Delaware corporation, having an office and place of business at 000 Xxxxx Xxxxxx, Xxxxx 000, Xxxxxxxxx, Xxxxxxxxxxxxx 00000, XXX (“COMPANY”)
MORPHOSYS and COMPANY may each individually be referred to as a “Party” and collectively as the “Parties”.
NOW and THEREFORE, the Parties hereby agree as follows:
1. | Capitalized terms used in this Amendment |
All capitalized terms used in this Amendment shall have the meaning ascribed to them in the Agreement, except as otherwise expressly stated herein.
2. | Modification of Section 9 “Joint-Bidding; Exclusive Arrangements” |
Section 9 of the Agreement is amended by deleting the phrase “Blackstone Life Sciences Advisors LLC or any of its affiliates”, and replacing it with the term “Permitted Advisors” as defined below.
3. | Modification of Section 14 “Certain Definitions” |
Section 14 of the Agreement is deleted in its entirety and shall be replaced by the following language:
with any other financial advisor or source of financing not covered by the term “Permitted Advisors”, then MorphoSys needs to notify COMPANY in writing (email to the COMPANY’s CEO, CBO, CFO, or CLO being sufficient notice for purposes hereof) by indicating the name of such additional financial advisor or source of financing and such additional financial advisor or source of financing is added to the term “Permitted Advisors” upon MorphoSys receiving an email from the COMPANY’s CEO, CBO, CFO, or CLO agreeing thereto.
4. | Performance under all other terms of the Agreement |
Except as expressly amended hereby, the Agreement shall continue in full force and effect. This Amendment is incorporated and made a part of the Agreement between MORPHOSYS and COMPANY. In the event of any conflict or inconsistency between the Agreement and this Amendment, the latter shall prevail.
5. |
This Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
MorphoSys AG | ||
/s/ Xxxxxxxxx Xxxxxxx | ||
Name: |
Xxxxxxxxx Xxxxxxx |
Title: |
SVP, General Counsel |
Date: |
April 14, 2021 |
Constellation Pharmaceuticals, Inc. | ||
/s/ Xxxxx Xxxxxxxxx | ||
Name: |
Xxxxx Xxxxxxxxx |
Title: |
Chief Legal Officer & General Counsel |
Date: |
April 14, 2021 |
2